1. Academic Validation
  2. Repeated dose 28-day oral toxicity study of moniliformin in rats

Repeated dose 28-day oral toxicity study of moniliformin in rats

  • Toxicol Lett. 2015 Feb 17;233(1):38-44. doi: 10.1016/j.toxlet.2014.11.006.
Martina Jonsson 1 Janne Atosuo 2 Marika Jestoi 3 Alexis V Nathanail 4 Ulla-Maija Kokkonen 5 Marjukka Anttila 6 Pertti Koivisto 4 Esa-Matti Lilius 2 Kimmo Peltonen 4
Affiliations

Affiliations

  • 1 Chemistry and Toxicology Research Unit, Finnish Food Safety Authority (Evira), Mustialankatu 3, Helsinki FI-00790, Finland. Electronic address: martina.jonsson@evira.fi.
  • 2 Department of Biochemistry and Food Chemistry, University of Turku, Turku FI-20014, Finland.
  • 3 Product Safety Unit, Finnish Food Safety Authority (Evira), Helsinki FI-00790, Finland.
  • 4 Chemistry and Toxicology Research Unit, Finnish Food Safety Authority (Evira), Mustialankatu 3, Helsinki FI-00790, Finland.
  • 5 Veterinary Virology Research Unit, Finnish Food Safety Authority (Evira), Helsinki FI-00790, Finland.
  • 6 Pathology Research Unit, Finnish Food Safety Authority (Evira), Helsinki FI-00790, Finland.
Abstract

Moniliformin is a Fusarium mycotoxin mainly produced by several species infecting grains in different climatic conditions. According to our previous studies, it is acutely toxic to rats, with an LD50 cut-off value of 25mg/kg b.w. To further assess the possible health risks of low dose exposure to moniliformin, a subacute oral toxicity study was conducted in Sprague-Dawley rats, adapting OECD guideline 407. Five dose groups and two satellite groups, each consisting of five male rats, were daily exposed to moniliformin by gavage. Two rats in the highest dose group, showed decreased activity followed by acute heart failure and death. The rats of the lower doses (<9mg/kg b.w.) showed no signs of toxicity. The daily intake of moniliformin strongly reduced the phagocytic activity of neutrophils in all dose groups. The decrease continued in the satellite group during the follow-up period, indicating a severe impact on the immune system and a LOAEL value of 3mg/kg b.w. for moniliformin. Moniliformin was rapidly excreted into urine, ranging between 20.2 and 31.5% daily and showed no signs of accumulation. The concentration of moniliformin in faeces was less than 2%, which suggests efficient absorption from the gastrointestinal tract.

Keywords

Excretion; Fusarium mycotoxins; Moniliformin; Sprague-Dawley rats; Subacute toxicity.

Figures
Products